HLS Therapeutics Inc.
HLTRF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $119,331 | $115,808 | $103,327 | $85,523 |
| - Cash | $10,778 | $12,153 | $17,734 | $17,456 |
| + Debt | $54,090 | $55,573 | $63,742 | $66,450 |
| Enterprise Value | $162,643 | $159,228 | $149,335 | $134,517 |
| Revenue | $13,511 | $14,171 | $12,623 | $15,542 |
| % Growth | -4.7% | 12.3% | -18.8% | – |
| Gross Profit | $10,974 | $11,666 | $10,225 | $12,857 |
| % Margin | 81.2% | 82.3% | 81% | 82.7% |
| EBITDA | $4,021 | $4,717 | $2,919 | $4,795 |
| % Margin | 29.8% | 33.3% | 23.1% | 30.9% |
| Net Income | -$3,918 | -$2,741 | -$4,436 | -$3,023 |
| % Margin | -29% | -19.3% | -35.1% | -19.5% |
| EPS Diluted | -0.12 | -0.088 | -0.14 | -0.095 |
| % Growth | -36.2% | 37.1% | -47.5% | – |
| Operating Cash Flow | $2,476 | $4,604 | $3,543 | $3,205 |
| Capital Expenditures | -$279 | -$1,087 | -$21 | -$12 |
| Free Cash Flow | $2,197 | $3,517 | $3,522 | $3,192 |